We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.1097 | 0.40% | 27.8097 | 27.905 | 27.52 | 27.86 | 45,382,575 | 21:25:14 |
From May 2019 to May 2024
Pfizer Inc. on Wednesday said a late-stage study of its Ibrance breast-cancer drug in combination with fulvestrant was stopped early after meeting its primary endpoint of demonstrating improvement in progression-free survival.
The pharmaceutical company said the decision to halt the study was based on an assessment by an independent data-monitoring committee.
Shares of Pfizer, up 17% over the past year, rose 1.8% in premarket trading.
Ibrance, also known as palbociclib, received accelerated approval from the U.S. Food and Drug Administration in February as a first-line treatment for women with a certain type of advanced or metastatic breast cancer.
Pfizer said it is in discussions with health regulators regarding a path for approval of Ibrance in combination with fulvestrant.
Write to Tess Stynes at tess.stynes@wsj.com
Access Investor Kit for Pfizer Inc.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US7170811035
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
